Atara Biotherapeutics reported a $74.3 million net loss, or $1.60 per share for the second quarter, a 46 percent increase from the previous second quarter and 10 cents higher than analyst estimates. The company spent $52.3 million on research and development during the period, up 56.5 percent from the second quarter of 2018. General and…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
